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Abstract
Objective: Vascular-derived cells represent an established cell source for tissue engineering of cardiovascular constructs. Previously, cell
isolation was performed by harvesting of vascular structures prior to scaffold seeding. Marrow stromal cells (MSC) demonstrate the ability to
differentiate into multiple mesenchymal cell lineages and would offer an alternative cell source for tissue engineering involving a less invasive
harvesting technique. We studied the feasibility of using MSC as an alternative cell source for cardiovascular tissue engineering. Methods:
Human MSC were isolated from bone marrow and expanded in culture. Subsequently MSC were seeded on bioabsorbable polymers and grown
in vitro. Cultivated cells and seeded polymers were studied for cell characterization and tissue formation including extracellular matrix
production. Applied methods comprised flow cytometry, histology, immunohistochemistry, transmission (TEM) and scanning electron micro-
scopy (SEM), and biochemical assays. Results: Isolated MSC demonstrated fibroblast-like morphology. Phenotype analysis revealed positive
signals for alpha-smooth muscle actin and vimentin. Histology and SEM of seeded polymers showed layered tissue formation. TEM demon-
strated formation of extracellular matrix with deposition of collagen fibrils. Matrix protein analysis showed production of collagen I and III. In
comparison to vascular-derived cell constructs quantitative analysis demonstrated comparable amounts of extracellular matrix proteins in the
tissue engineered constructs. Conclusions: Isolated MSC demonstrated myofibroblast-like characteristics. Tissue formation on bioabsorbable
scaffolds was feasible with extracellular matrix production comparable to vascular-cell derived tissue engineered constructs. It appears that
MSC represent a promising cell source for cardiovascular tissue engineering.q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Currently valve replacement is an effective treatment
using mechanical or biological protheses [1]. However,
there are certain limitations regarding long-term benefit.
Mechanical valves are associated with a substantial risk of
thromboembolism while biological valves lack the ability to
repair, grow, or remodel resulting in structural dysfunction
[2,3].
Tissue engineering offers a promising approach to over-
come these limitations by trying to create viable valve struc-
tures with a thromboresistant surface and a living
interstitium with repair and remodeling capabilities [4].
Several groups reported the feasibility of creating autolo-
gous living cardiovascular structures by seeding cells on
synthetic polymer, collagen or xenogenic scaffolds [5–8].
Previously our group demonstrated the feasibility of tissue
engineering living heart valve constructs by seeding bioab-
sorbable polymer scaffolds [9]. However, all of these
approaches are based on vascular-derived cell sources
with certain shortcomings. Harvesting of the cells prior to
scaffold seeding necessitates the sacrifice of an intact vessel.
Furthermore, vascular-derived cells demonstrate different
characteristics compared to valve interstitial cells, qualities
which may be vital to the development and function of a
tissue engineered heart valve [10]. Due to these limitations
we investigated the feasibility of applying marrow stromal
cells (MSC) as an alternative cell source for tissue engineer-
ing. The usage of MSC may offer several advantages by: (i)
showing characteristics of multipotent progenitor cells
which are able to differentiate into a variety of mesenchy-
mal cell types; (ii) easy collection and isolation methods
avoiding the sacrificing of intact cardiovascular structures;
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and (iii) demonstrating immunological unique characteris-
tics allowing persistence in an allogenic setting [11–13].
2. Materials and methods
2.1. Cell isolation
MSC were isolated from human bone marrow by washing
in Dulbecco’s phosphate buffered saline (DPBS, Gibco) for
10 min at 1500 rpm. The cells were recovered after centri-
fugation and resuspended in DPBS. A low-density cell frac-
tion of bone marrow was obtained by centrifugation of the
cell suspension over a Ficoll step gradient (density 1.077 g/
ml) (Ficoll-Histopaque 1077, Sigma) at 1500 rpm for 10
min. The nucleated cells were collected from the interface,
diluted with two volumes of DPBS and centrifuged at 1500
rpm for 10 min. Following, the cells were resuspended,
counted and plated at 200 000 cells/cm2.
2.2. Cell cultivation
The isolated cell fraction was cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Gibco) supplemented
with 10% fetal bovine serum (HyClone), penicillin
(Gibco), and streptomycin (Gibco) in tissue flasks (Corning,
Inc.) and left to adhere at 378C for 4–5 h. The non-adherent
cells floated off, while mesenchymal cells adhered, spread,
and grew. Medium was replaced at 24 and 72 h and every 6
days following. Daily growth progress was monitored by
phase-contrast microscopy. The cells were serially passaged
and expanded in a humidified incubator at 378C with 5%
CO2. Sufficient cell numbers for cell seeding on bioabsorb-
able polymer scaffolds were obtained after 21–28 days.
2.3. Bioabsorbable polymer scaffolds
Non-woven polyglycolic-acid mesh (PGA, thickness: 1.0
mm, specific gravity: 69 mg/cm3, Albany Int.) was coated
with poly-4-hydroxybutyrate (P4HB, MW: 1 £ 106, PHA
4400, TEPHA Inc., Cambridge, MA). From the PGA/
P4HB composite scaffold material strips (20 £ 15 mm)
were cut and cold gas sterilized with ethylene oxide.
2.4. Cell seeding and in vitro culture of polymer constructs
MSC were seeded onto the polymer scaffolds (n ¼ 6)
with an approximate cell density between 4.5–5.5 £ 106
per cm2 and cultured in nutrient medium (DMEM, Gibco)
for 14 days in a humidified incubator (378C, 5% CO2).
2.5. Analysis of MSC cultures
2.5.1. Flow cytometry (FACS)
A single cell suspension of MSC was prepared for FACS.
0.5–1 £ 106 cells in 100 ml phosphate buffered saline (PBS)
plus BSA were incubated with saturating concentrations of
monoclonal antibodies CD 31-FITC (Sigma, St. Louis),
LDL-Dil (Biomedical Technologies Inc, Stoughton, MA),
CD 14-FITC (Beckon Dickinson, San Jose, CA). For intra-
cellular staining, cells were permeabilized with ethanol for
30 min and incubated with monoclonal antibodies against
ASMA (Sigma, St. Louis) and vimentin (NeoMarkers,
Fremont). Following washing, staining with a secondary
FITC-conjugated IgG goat-anti-mouse antibody (Chemi-
con, Temecula, CA) was performed for 30 min. Forward
and side scatter gates were set to exclude debris and
10 000 gated events were counted per sample. Correspond-
ing isotype and positive controls were performed for each
antibody. Cells were analyzed with the flow cytometer
FACS-Calibur (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Data analysis was performed
with the CELL QUEST software program (Becton Dickin-
son Immunocytometry Systems, San Jose, CA). Expression
levels were calculated as mean fluorescence intensity ratio
(MFIR) defined as mean fluorescence intensity of the
studied antibodies divided by mean fluorescence intensity
of corresponding isotype controls.
2.5.2. Histology and immunohistochemistry
Isolated MSC were cultivated onto glass coverslips in
nutrient medium (DMEM, Gibco). After 2–3 days cells
were washed with PBS and fixed in 4% paraformaldehyde
for 10 min. Cells were examined histologically by hematox-
ylin & eosin (H & E) and Trichrome-masson stain. Immuno-
histochemistry was performed by incubation with
monoclonal mouse antibodies for ASMA (Sigma, St.
Louis), vimentin (NeoMarkers, Fremont), desmin (NeoMar-
kers, Fremont), collagen I–IV (Oncogen, Boston), and elastin
(Sigma, St. Louis). Incubation with a secondary biotin-
labeled goat-anti-mouse IgG antibody (Sima, St. Louis)
was performed and the signal was developed with the
avidin-peroxidase system (ABC kit, Vector Lab, Burlingame
CA). Prior to intracellular staining, permeabilization of the
cells was performed by incubation with 0.1% Triton (Sigma,
St. Louis) for 10 min.
2.6. Analysis of MSC-seeded polymer constructs
2.6.1. Histology and immunohistochemistry
After 2 weeks in culture, sections of MSC seeded polymer
scaffold strips were fixed in 4% phosphate-buffered formalin
and embedded in paraffin. Paraffin sections were cut at 5-mm
thickness and studied by H & E and Trichrome-masson stain.
Immunohistochemistry was performed as described above
by incubation with monoclonal mouse antibodies for
ASMA, vimentin, desmin, collagen I–IV and elastin.
2.6.2. Scanning and transmission electron microscopy
Additional samples of MSC-seeded polymer strips were
fixed in 2% glutaraldehyde (Sigma, St. Louis) and dehy-
drated in acetone followed by drying in carbon dioxide for
scanning electron microscopy (SEM) and transmission elec-
tron microscopy (TEM).
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2.6.3. Biochemical assays
Cellular and extracellular components of the MSC-
seeded constructs were analyzed by biochemical assays
and compared to vascular-derived cell (VC) seeded
constructs. VC seeded constructs were identically generated
as MSC-seeded constructs by using jugular venous fibro-
blasts. Total DNA was isolated and purified by sequential
organic extractions with phenol and phenol/chloroform/
isoamyl alcohol and quantitated by spectrophotometry.
For determination of total collagen content, the tissue was
completely acid-digested and total 5-hydroxyproline was
measured. Total proteoglycan/glycosaminoglycan (GAG)
and elastin content were quantitated with a BLYSCANe
and FASTINe assay (Biocolor, Belfast, Ireland) after tissue
extraction [14]. Data of biochemical testing was statistically
analyzed by SPSS 8.0 Software and expressed as mean ^
standard error of the mean. An unpaired t-test (Student t-
test) was performed, considering a P-value ,0.05 as statis-




Isolated cells appeared small and round with a tendency
to grow in clusters. Non-adherent cells were removed by
medium change at 24 h and every 4 days thereafter. Elon-
gated cells with fibroblast-like morphology appeared after
72 h and reached confluence after 10–14 days.
3.2. Flow activated cell scanning
Table 1 shows the results of FACS analysis for MSC.
Flow cytometry characterization of MSC demonstrates no
significant difference in expression of ASMA (MFIR 3.66)
and vimentin (MFIR 12.59) compared to vascular-derived
myofibroblasts. No positive signal was detected for CD 14
(MFIR 1.13), CD 31 (MFIR 1.1), and LDL (MFIR 1.94)
among the isolated cell population (Table 1).
3.3. Histology and immunophenotyping of MSC
H & E and Trichrome-masson staining of fixed cells
demonstrated the deposition of extracellular matrix through-
out the cell culture. Immunohistochemistry showed the
expression of ASMA and vimentin by MSC. The deposition
of collagen I and III was detected by positive staining. In
contrast, no signal was observed following antibody stain-
ing for desmin, collagen II, IV, and elastin.
3.4. Histology and immunohistochemistry of MSC-seeded
polymer constructs
H & E and Trichrome-masson staining of the MSC-
seeded polymer constructs showed a layered tissue forma-
tion and a dense upper layer with deposition of extracel-
lular matrix proteins. Irregular cellular ingrowth was
observed into less cellularized deeper parts of the polymer
strips (Figs. 1A,B). Immunohistochemistry of MSC-seeded
constructs showed positive staining for ASMA and vimen-
tin (Figs. 1C,D). Extracellular matrix analysis demon-
strated the deposition of collagen I and III (Figs. 1E,F).
No positive staining was studied for desmin, collagen II,
IV, and elastin.
3.5. Transmission and scanning microscopy
TEM of sections of MSC polymer constructs showed
secretionally active fibroblasts with deposition of collagen
fibrils (Fig. 2A). SEM revealed loose tissue formation and
demonstrated the degradation of the polymer scaffold by
multiple hydrolytic breakages and fragmentation of the
polymer fibers (Fig. 2B).
3.6. Biochemical assays
Results of the biochemical assays are shown in Fig. 3.
DNA content of the MSC constructs (2.7 mg/mg dry tissue
^0.6) was significantly superior (P , 0:01) compared to
VC constructs (0.9 mg/mg dry tissue ^0.5). Biochemical
assays detected a hydroxyproline content of MSC constructs
of 3.1 mg/mg dry tissue ^0.4 which was comparable to VC
constructs (2.8 mg/mg dry tissue ^0.5). The quantitative
analysis of the glycosaminoglycan amount revealed 4.9
mg/mg dry tissue ^0.7 not significantly different
(P . 0:05) to VC constructs (5.8 mg/mg dry tissue ^0.6).
Elastin was not detectable in MSC- and VC-constructs.
4. Discussion
Presently, vascular-derived cells represent an established
cell source for seeding of tissue engineered cardiovascular
constructs. By using venous or arterial vascular cells, func-
tional tissue engineered patches, vascular grafts, and heart
valves were generated [5,7,15]. In prior in-vitro and in-vivo
studies Hoerstrup et al. demonstrated the feasibility of tissue
engineering a complete and living autologous heart valve by
using myofibroblasts of carotid artery origin [9]. Following
5 months implantation in sheep the tissue engineered valves
functioned satisfactorily in-vivo while tissue formation
gradually evolved to resemble native pulmonary valve
morphology and histology. However, there is evidence
that native heart valves consist of a mixed population of
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Table 1
MFIR of FACS analysis
Antigen MSC Positive controls
Vimentin 12.59 15.67 (myofibroblasts)
ASMA 3.66 3.53 (myofibroblasts)
CD 14 1.13 4.6 (PBMC)
LDL 1.94 7.19 (endothelial cells)
CD 31 1.1 55.58 (endothelial cells)
interstitial cells (IC) which show specific and unique char-
acteristics different to vascular-derived fibroblasts [16,17].
Recently, Taylor et al. demonstrated the feasibility of using
IC for tissue engineering [8]. A possible clinical application
of creating a tissue engineered valve with IC is limited by
using non-autologous IC.
Given these problems it appears that the appropriate cell
source for tissue engineering of heart valves is still unclear.
In the present study we evaluated the feasibility of using an
alternative cell source for tissue engineering heart valves –
mesenchymal stromal cells.
Isolation of MSC was easy to perform avoiding the sacrifi-
cing of an intact vascular structure. Isolated cells appeared
small, round, and elongated with a fibroblast-like morphol-
ogy. After 72 h cells appeared to grow in a colony-forming
pattern. Identical morphological characteristics and growth
pattern are reported for mesenchymal precursor cells by other
studies using a similar isolation procedure [18,19]. Analysis
of the cell population showed characteristics of a myofibro-
blast-like differentiation. MSC expressed ASMA, vimentin
and the deposition of collagen I and III was observed. MSC
did not stain positive for the monoclonal antibody against
desmin, a muscle cell marker. A similar staining pattern is
reported for valve IC by Taylor et al. [8]. FACS analysis did
not detect any CD 14, CD 31, or LDL positive cells, indicat-
ing the absence of myeloid and endothelial cell differentia-
tion of MSC. Furthermore, we did not observe any positive
staining for collagen II, implying the absence of an osteo-
blastoid differentiation of the isolated cells.
The formation of tissue by MSC showed identical results
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Fig. 1. Histology and Immunohistochemistry of MSC culture and polymer constructs. H & E (A); and Trichrome-masson (B) staining show cells with a
fibroblast morphology and layered tissue formation with deposition of extracellular matrix proteins. MSC-seeded polymer constructs show a irregular cellular
growth into less cellularized deeper layers. Immunohistochemical staining demonstrated the expression of ASMA (C); and vimentin (D). Extracellular matrix
analysis demonstrated the deposition of collagen I (E); and III (F).
compared to vascular-derived cells seeded on polymer
constructs after 14 days in culture. We observed a layered
tissue structure formation with a dense upper layer. Overall,
morphology and ultra-structural analysis showed good cell-
polymer adhesion and growth of MSC into deeper parts of
the polymer strips. Furthermore, the gradual biodegradation
of the scaffold and the replacement by viable tissue was
observed. Results of biochemical assays demonstrated no
significantly different amount of extracellular matrix
proteins of MSC polymer constructs compared to VC
seeded constructs.
In previous studies it was demonstrated that exposure of
tissue engineered heart valve constructs to a pulsatile flow
significantly improved tissue development and mechanical
properties [7,20]. A homogenous, dense tissue developed
resembling native valve morphology. In addition, biochem-
ical analysis of the tissue engineered heart valves showed
comparable values to native tissue. Given these results we
anticipate that exposure of MSC-seeded constructs to a
biomimetic pulsatile flow system will demonstrate
improved tissue formation and differentiation. We also
believe that future animal experiments are required to eval-
uate the remodelling capacity, the growth potential, and
long-term function of MSC-seeded tissue engineered
constructs under physiologic conditions.
In conclusion, this study demonstrates the feasibility of
using MSC as a new alternative cell source for tissue engi-
neering. Cell isolation was easy to perform without the need
to sacrificing intact vascular structures. MSC showed char-
acteristics of myofibroblast-like differentiation with neo-
tissue formation comparable to tissue engineered constructs
based on vascular-derived cells.
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Fig. 2. Transmission and scanning electron microscopy. (A) TEM of sections of MSC polymer constructs shows cell elements typical of viable, secretionally
active myofibroblasts with deposition of collagen fibrils (arrow). (B) SEM revealed loose tissue formation with good cell-polymer-attachments (arrow) and
demonstrated the degradation of the polymer scaffold by multiple hydrolytic breakages and fragmentation of the polymer fibers (*).
Fig. 3. Biochemical assays.
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Appendix A. Conference discussion
Mr S. Stoica (Cambridge, UK): A very elegant concept. I thought the
histology slides were most convincing. Did you use a negative and positive
control for your monoclonal antibodies?
Dr Kadner: Certainly, we were performing both negative and positive
controls.
Dr G. Gerosa (Padova, Italy): I congratulate you. You did very excellent
work. I would like to ask you, the myofibroblasts that you identified with
your immunohistochemistry were fetal type or adult type?
Dr Kadner: The bone marrow stromal cells were adult type, and the
vascular-derived cells came from saphenous vein.
Dr A. Haverich (Hannover, Germany): I have a more general question,
and that is that many other researchers in other fields use the same sort of
cells and they are making liver and they are making pancreas, so they are
using pluripotent neural stem cells and cellularized tissues out of that. What
do you think will be the necessary environment for these cells when used
for cardiovascular applications?
Dr Kadner: I would have to speculate about this. It appears that initially
these cells take spontaneously a fibroblast-like lineage. However, other
groups have shown that by using such cell medium supplements as dexa-
methasone, insulin or transforming growth factor beta 3 that you can induce
chondrocytic, osteocytic or adipocytic lineages. What would be very inter-
esting for cardiovascular tissue engineering is the differentiation of these
cells in a endothelial lineage.
Dr B. Messmer (Aachen, Germany): I think one of the most important
things is the expression of collagen. Can you explain why you have an
inhomogenous expression of collagen 1 and 2, which you have shown;
you didn’t show 3 and 4? This is very inhomogenous, and this may be a
disadvantage.
Dr Kadner: I agree with you, and I think the reason is that these
constructs were cultured only for a very brief period, for 7 days under
steady conditions. In this context I would like to refer to a talk my collea-
gue, Simon Hoerstrup, is giving tomorrow. He will present our data for
using these cells for creating tissue engineered heart valve constructs,
which were cultured under dynamic conditions for an extended period of
time.
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